Search clinical trials for: Placebo for SNG001

Total 69491 results

Beijing Inno Medicine Co., Ltd.

Recruiting

A First-in-human Study of YN001 in Healthy Volunteers

Cardiovascular Diseases

Australia
Samjin Pharmaceutical Co., Ltd.

Completed

A Phase 1 Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

Healthy

Korea, Republic of
SinoMab BioScience Ltd

Unknown

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Health Subject

Autoimmune Diseases

Australia
Samjin Pharmaceutical Co., Ltd.

Completed

Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

Healthy
Pinteon Therapeutics, Inc
United States Department of Defense

Terminated

Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)

Traumatic Brain Injury

United States
Synairgen Research Ltd.

Completed

Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection

SARS-CoV-2

United Kingdom
Synairgen Research Ltd.

Completed

Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19 (SPRINTER)

COVID-19 | Severe Acute Respiratory Syndrome Coronavirus 2

United Kingdom, Italy, United States, Portugal, Israel, Germany, Belgium, India, Spain, Netherlands, Argentina, Brazil, Colombia, France, Mexico, Romania, Serbia
Zhuhai Trinomab Pharmaceutical Co., Ltd.

Not yet recruiting

A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants

Respiratory Syncytial Virus Infections

China
Trinomab Biotech Co., Ltd.

Recruiting

A Study of TNM001 in Chinese Healthy Preterm and Term Infants

Respiratory Syncytial Virus Infections

China
Pinteon Therapeutics, Inc

Completed

Safety and Tolerability of PNT001 in Healthy Adults

Healthy

United States
Spinogenix
Avance Clinical Pty Ltd.

Not yet recruiting

Study of SPG601 in Adult Men With Fragile X Syndrome

Fragile X Syndrome

United States
Syntimmune, Inc.

Completed

A Study of SYNT001 in Healthy Volunteers

Healthy

United States
Hangzhou Sumgen Biotech Co., Ltd.

Recruiting

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)

China
Samjin Pharmaceutical Co., Ltd.

Completed

Clinical Study to Investigate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome.

Dry Eye Syndrome

Korea, Republic of
Samjin Pharmaceutical Co., Ltd.

Completed

Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome

Primary Sjögren's Syndrome (pSS)

Korea, Republic of
Shanghai Synvida Biotechnology Co.,Ltd.

Recruiting

A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.

Idiopathic Pulmonary Fibrosis

China
Neuraltus Pharmaceuticals, Inc.

Completed

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Neuraltus Pharmaceuticals, Inc.

Completed

Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AIDS Clinical Trials... and other collaborators

Completed

ACTIV-2: A Study for Outpatients With COVID-19

Covid19 | Coronavirus

United States, Argentina, Brazil, Guatemala, Mexico, Philippines, Puerto Rico, South Africa, Canada
Shanghai Runshi Pharmaceutical Technology Co., Ltd

Not yet recruiting

A Study of Simmitinib Plus SG001 in Advanced Solid Tumors

Advanced Solid Tumor

China
Beau Nakamoto
Neuraltus Pharmaceuticals, Inc.

Terminated

NP001, Alzheimer's Disease, and Blood Markers of Inflammation

Alzheimer Disease

United States
University of Zurich
Ixodes GmbH; Appletree AG

Completed

Safety, Skin and Plasma Concentration of Azithromycin Dermal Formulation (IXO-01)

Lyme Disease

Switzerland
Neuraltus Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

Amyotrophic Lateral Sclerosis

United States, Canada
Newron Sweden AB
Quintiles, Inc.; Medtronic

Completed

A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease

Parkinson's Disease

Sweden
Kun Sun

Recruiting

A Clinical Study Evaluating the Safety and Efficacy of SKG0201 Injection in Patients With Spinal Muscular Atrophy Type 1

Spinal Muscular Atrophy 1

China
SP Nutraceuticals Inc.
Canadian Glycomics Network (GlycoNet)

Completed

Safety Evaluation of β-arbutin in Healthy Human Subjects

Healthy Volunteers

Canada
Renovo

Completed

Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites

Cicatrix | Wound Healing

United Kingdom
Renovo

Completed

Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)

Cicatrix | Wound Healing

United Kingdom
Alexion Pharmaceuticals

Withdrawn

ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia

Warm Autoimmune Hemolytic Anemia

United States
Renovo

Completed

Investigation of the Safety, Dosing Frequency and Anti-Scarring Potential of Two Concentrations of Intradermal Avotermin (Juvista)

Cicatrix | Wound Healing | Re-epithelialization

United Kingdom
Renovo

Completed

Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects

Cicatrix | Wound Healing

United Kingdom
Alexion

Withdrawn

Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia

Warm Autoimmune Hemolytic Anemia

United States
Strekin AG

Completed

Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL

Acute Hearing Loss

Switzerland, Czechia, Germany
Renovo

Completed

A Trial to Compare the Efficacy of Two Formulations of Avotermin Against Placebo (RN1006)

Scar Improvement

United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients (STAND)

Sickle Cell Disease (SCD)

United States, United Kingdom, Germany, Spain, Greece, Italy, Brazil, Lebanon, Turkey, Belgium, France, Jordan, India, Finland, Canada, Colombia, Netherlands, Oman, South Africa, Panama, Ghana
ARTBIO Inc.

Completed

Phase 0/1 Study of 212Pb-NG001 in mCRPC

Metastatic Castration-resistant Prostate Cancer

Norway
Materia Medica Holding

Completed

Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections

Acute Upper Respiratory Infections

Russian Federation
Symphogen A/S
Swedish Orphan Biovitrum

Completed

Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

Immune Thrombocytopenic Purpura

United States, Belgium, Germany, India, Israel, Poland, Romania, Russian Federation, Serbia, Spain, Ukraine, United Kingdom
Newron Sweden AB

Terminated

A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.

Parkinson's Disease

Sweden
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

Attention-Deficit Hyperactivity Disorder

Japan
NKGen Biotech, Inc.

Recruiting

Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

Moderate Alzheimer Disease

United States
Li Xiaorong
Shanghai Refreshgene Technology Co., Ltd.

Recruiting

The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR)

PDR - Proliferative Diabetic Retinopathy

China
SCG Cell Therapy Pte. Ltd.

Recruiting

A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma (TCR-T)

Hepatocellular Carcinoma Recurrent | Hepatitis B Virus Related Hepatocellular Carcinoma

United States, Singapore, Hong Kong
Blue Note Therapeutics
Durham VA Health Care System

Terminated

BNT001 Digital Therapeutic Feasibility Pilot Study

Cancer

United States
Spruce Biosciences

Completed

A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens

Polycystic Ovary Syndrome

United States
Shenzhen Shenxin Biotechnology Co., Ltd

Not yet recruiting

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

Herpes Zoster
Spruce Biosciences

Active, not recruiting

A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

Congenital Adrenal Hyperplasia

United States, Australia, Brazil, Estonia, Germany, Korea, Republic of, Latvia, Lithuania, Poland, Romania, Spain, Sweden, Turkey, Canada, Italy, United Kingdom
Livzon Pharmaceutical Group Inc.
Palm Beach CRO; Keystone Bioanalytical, Inc.

Completed

Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US

Solid Tumor Refractory to Standard Therapy

United States
Neuracle Genetics, Inc
ORA, Inc.

Recruiting

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

Age-Related Macular Degeneration

Canada
Spruce Biosciences

Active, not recruiting

A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

Congenital Adrenal Hyperplasia

United States, Australia, Brazil, Canada, Denmark, Estonia, Germany, Ireland, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Poland, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom

Search clinical trials for: Placebo for SNG001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations